Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Flo Health’s GDPR Compliance and Privacy, Security Protections Stand Up to Independent ISO ScrutinyLONDON, August 26, 2026--Flo Health, the #1 female health app used by more than 300 million people worldwide, has completed its annual ISO 27001 and ISO 27701 audits, which returned zero findings. This means independent auditors identified no areas for improvement in the company's privacy and security management systems.
- ViiV HealthcareU.S. FDA approves ViiV Healthcare’s Tivicay PD, helping close a critical HIV treatment gap for young childrenLONDON, August 26, 2026--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced that the U.S. Food and Drug Administration (FDA) has approved Tivicay PD (dolutegravir (DTG)), for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in paediatric patients (treatment-naïve or -experienced but integrase strand transfer inhibitor (INSTI)-naïve) weighing at least 2 kg.
- Berger MontagueBerger Montague PC Investigates Hims & Hers Health, Inc.'s Board of Directors for Breach of Fiduciary Duty (HIMS)National plaintiffs' law firm Berger Montague PC announces an investigation into the Board of Directors of Hims & Hers Health, Inc. (NYSE: HIMS) ("Hims & Hers" or the "Company") for potential breaches of fiduciary duties owed to the Company and its shareholders. The investigation is focused on whether the Company improperly shared private user health data with advertisers, engaged in deceptive billing practices, and made...
- NeOnc’s Clinical Story Is Now the Main EventNeOnc’s (NASDAQ: NTHI) Clinical Story Is Now the Main Event
- VolitionRx LimitedVolition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in SepsisPublished in Critical Care Medicine, findings confirm high-predictive accuracy for severe sepsis outcomes, driving commercial momentum across Volition's $2.8 billion addressable market. — VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a...
- Candel TherapeuticsCandel Therapeutics to Present at September Investor ConferencesCandel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and Chief Executive Officer, will participate in analyst-led fireside discussions and one-on-one meetings at upcoming investor conferences in September 2026.
- Sino BiologicalMonod Bio Licenses AI-designed Protein Technologies to SignalChem Biotech for Custom Discovery AssaysMonod Bio, a Seattle-based AI-enabled protein design company, and SignalChem Biotech Inc., a wholly-owned subsidiary of Sino Biological, Inc. (SZSE: 301047), today announced a non-exclusive licensing agreement covering Monod Bio's...
- PharmaForceIQPharmaForceIQ Launches Optichannel 360, the First AI-Native Answer-to-Action Engine for Pharma Commercial TeamsPharmaForceIQ has today introduced Optichannel 360, an AI-native commercial execution platform that connects field and digital marketing, including a new measurement answer-to-action workflow. The Optichannel 360 platform is built as a broader...
- NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present data from its obicetrapib development program at the European Society of Cardiology (ESC) Congress 2026, taking place August 28 – 31, 2026 in Munich, Germany.
- Tvardi TherapeuticsTvardi Therapeutics to Participate in Upcoming Investor EventsTvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced that management will participate in the following upcoming investor events:
- Form-8.3 ADVANCED MEDICAL SOLUTIONS GROUP PLC - 25 08 2026 - (CGWL)FORM 8.3
- HepaRegeniX Receives Orphan Drug Designation for Darizmetinib for the Prevention of Post-Hepatectomy Liver FailureU.S. FDA Orphan Drug Designation underscores darizmetinib’s potential to address a significant unmet need following liver resection